Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma-Reference-Cited by-同舟云学术

Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma

Published:2022-10-18 Issue:2 Volume:53 Page:172-178
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatology Research

Author:

Tomonari Tetsu¹^ORCID,Tani Joji²,Ogawa Chikara³,Deguchi Akihiro⁴,Senoh Tomonori⁵,Moriya Akio⁶,Shibata Hiroshi⁷,Fukuno Hiroshi⁸,Tanaka Hironori¹^ORCID,Tanaka Takahiro¹,Taniguchi Tatsuya¹,Sogabe Masahiro¹,Kawano Yutaka¹,Morishita Akihiro²^ORCID,Takaguchi Koichi⁵,Miyamoto Hiroshi¹,Sato Yasushi⁹^ORCID,Masaki Tsutomu²,Takayama Tetsuji¹

Affiliation:

1. Department of Gastroenterology and Oncology Tokushima University Graduate School of Biomedical Sciences Tokushima Japan

2. Department of Gastroenterology and Neurology Kagawa University Graduate School of Medicine Kagawa Japan

3. Department of Gastroenterology and Hepatology Takamatsu Red Cross Hospital Takamatsu Japan

4. Department of Gastroenterology Kagawa Rosai Hospital Marugame Japan

5. Department of Hepatology Kagawa Prefectural Central Hospital Takamatsu Japan

6. Department of Gastroenterology Mitoyo General Hospital Kanonji Japan

7. Department of Gastroenterology Tokushima Prefectural Central Hospital Tokushima Japan

8. Department of Gastroenterology Tokushima City Hospital Tokushima Japan

9. Department of Community Medicine for Gastroenterology and Oncology Tokushima University Graduate School of Biomedical Sciences Tokushima Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hepr.13845

Reference20 articles.

1. The role of molecular enrichment on future therapies in hepatocellular carcinoma

2. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

3. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives;Discover Oncology;2024-07-03

2. Insights in Molecular Therapies for Hepatocellular Carcinoma;Cancers;2024-05-10

3. Successful second‐line treatment with cabozantinib for hepatocellular carcinoma harboring cytoplasmic mesenchymal–epithelial transition factor amplification;Hepatology Research;2023-10-24

4. Characteristics of cabozantinib treatment in advanced hepatocellular carcinoma;Liver Cancer International;2023-09

5. Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis;Drugs - Real World Outcomes;2023-07-19